Puma Biotechnology (NASDAQ:PBYI) Sets New 12-Month High – Still a Buy?

Posted by Geri Gentry on Sep 2nd, 2026

Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $9.73 and last traded at $9.70, with a volume of 224766 shares changing hands. The stock had previously closed at $9.35.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on PBYI shares. TD Cowen increased their target price on Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 21st. Two analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.

Get Our Latest Stock Report on Puma Biotechnology

Puma Biotechnology Stock Performance

The firm has a fifty day simple moving average of $8.43 and a 200 day simple moving average of $7.47. The company has a market capitalization of $500.20 million, a PE ratio of 18.63 and a beta of 1.24.

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.15. The business had revenue of $56.50 million for the quarter, compared to the consensus estimate of $53.00 million. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%. Research analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Allison Dorval sold 11,610 shares of the business’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $7.20, for a total value of $83,592.00. Following the completion of the sale, the director owned 90,780 shares in the company, valued at approximately $653,616. The trade was a 11.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas M. Hunt sold 8,460 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $8.26, for a total transaction of $69,879.60. Following the completion of the sale, the insider owned 196,841 shares of the company’s stock, valued at approximately $1,625,906.66. This represents a 4.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 132,028 shares of company stock valued at $1,006,711 over the last quarter. 22.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Puma Biotechnology

A number of large investors have recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in Puma Biotechnology during the 2nd quarter worth $35,000. Royal Bank of Canada raised its stake in Puma Biotechnology by 244.5% in the first quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 3,066 shares during the last quarter. California State Teachers Retirement System raised its stake in Puma Biotechnology by 110.2% in the second quarter. California State Teachers Retirement System now owns 4,898 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 2,568 shares during the last quarter. Philadelphia Investment Partners LLC acquired a new stake in Puma Biotechnology in the second quarter worth about $65,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Puma Biotechnology by 39.7% during the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 2,290 shares during the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

(Get Free Report)

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.